Background: In humans, a T→C transition at nucleotide 29 in the region encoding the signal peptide sequence of the transforming growth factor (TGF)-β1, which results in a Leu→Pro substitution at codon 10, has been associated with myocardial infarction. Aims/Methods: In the present study, we genotyped 284 unrelated, nondiabetic Swedish men born in 1944 to assess the impact of the Leu10Pro variant on obesity, including abdominal obesity, and estimates of insulin, glucose and lipid metabolism as well as blood pressure. Results: The frequency of the Pro10 variant was 38.9% (95% CI 32.2–46.0%), and the distribution of genotypes was in Hardy-Weinberg equilibrium. Data analysis showed that heterozygotes had significantly higher body mass index compared to homozygous carriers to the Leu10 variant. In addition, homozygous carriers of the Leu10 variant had significantly lower abdominal sagittal diameter than both Leu10Pro and Pro10Pro carriers. We also found that heterozygotes had significantly higher fasting insulin values as well as higher HOMA insulin-resistance index in comparison to homozygous carriers of the Leu10. Fasting glucose levels were significantly higher in subjects with the Pro10Pro variant compared to subjects with either the Leu10Leu or Leu10Pro variant. Conclusion: These findings suggest that the Pro10 allele in the TGF-β1 gene pathway might contribute to prevalent diseases such as obesity and type 2 diabetes mellitus.

Keywords:
Blood pressure, Genes, Glucose, Insulin, Obesity, Polymorphism, Transforming growth factor
1.
Blobe GC, Schiemann WP, Lodish HF: Role of transforming growth factor-β in human disease. N Engl J Med 2000;342:1350–1358.
2.
Reeves WB, Andreoli TE: Transforming growth factor-β contributes to progressive diabetic nephropathy. Proc Natl Acad Sci USA 2000;97:7667–7669.
3.
Ziyadeh FN, Hoffmann BB, Han DC, Iglesias-de la Cruz MC, Hong SW, Isono M, Chen S, McGowan TA, Sharma K: Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-β antibody in db/db diabetic mice. Proc Natl Acad Sci USA 2000;97:8015–8020.
4.
Hodge AM, de Courten MP, Zimmet P: Obesity and type 2 diabetes mellitus; in Björntorp P (ed): The International Textbook of Obesity. Chichester, Wiley, 2001, pp 351–364.
5.
Samad F, Pandey M, Loskutoff DJ: Tissue factor gene expression in the adipose tissues of obese mice. Proc Natl Acad Sci USA 1998;95:7591–7596.
6.
Alessi MC, Bastelica D, Morange P, Berthet B, Leduc I, Verdier M, Geel O, Juhan-Vague I: Plasminogen activator inhibitor-1, transforming growth factor-β1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes 2000;49:1374–1380.
7.
Gottschling-Zeller H, Birgel M, Scriba D, Blum WF, Hauner H: Depot-specific release of leptin from subcutaneous and omental adipocytes in suspension culture: Effect of tumor necrosis factor-α and transforming growth factor-β1. Eur J Endocrinol 1999;141:436–442.
8.
Derynck R, Jarrett JA, Chen EY, Eaton DH, Bell JR, Assoian RK, Roberts AB, Sporn MB, Goeddel DV: Human transforming growth factor-β complementary DNA sequence and expression in normal and transformed cells. Nature 1985;316:701–705.
9.
Fujii D, Brissenden JE, Derynck R, Francke U: Transforming growth factor-β gene maps to human chromosome 19 long arm and to mouse chromosome 7. Somat Cell Mol Genet 1986;12:281–288.
10.
Cambien F, Ricard S, Troesch A, Mallet C, Generenaz L, Evans A, Arveiler D, Luc G, Ruidavets JB, Poirier O: Polymorphisms of the transforming growth factor-β1 gene in relation to myocardial infarction and blood pressure: The Etude Cas-Témoin de l’Infarctus du Myocarde (ECTIM) Study. Hypertension 1996;28:881–887.
11.
Yokota M, Ichihara S, Lin TL, Nakashima N, Yamada Y: Association of a T29→C polymorphism of the transforming growth factor-β1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation 2000;101:2783–2787.
12.
Verner K, Schatz G: Protein translocation across membranes. Science 1988;241:1307–1313.
13.
Rosmond R, Chagnon YC, Holm G, Chagnon M, Perusse L, Lindell K, Carlsson B, Bouchard C, Björntorp P: Hypertension in obesity and the leptin receptor gene locus. J Clin Endocrinol Metab 2000;85:3126–3131.
14.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–419.
15.
Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T, Muggeo M: Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: Studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000;23:57–63.
16.
Lario S, Inigo P, Campistol JM, Poch E, Rivera F, Oppenheimer F: Restriction enzyme-based method for transforming growth factor-β1 genotyping: Nonisotopic detection of polymorphisms in codons 10 and 25 and the 5′-flanking region. Clin Chem 1999;45:1290–1292.
17.
Spjotvoll E, Stoline M: An extension of the T-method of multiple comparison to include the cases with unequal sample sizes. J Am Stat Assoc 1973;68:976–978.
18.
Sjöstrom L, Lönn L, Chowdhury B, Grangård U, Lissner L, Sjöström D, Sullivan L: The sagittal diameter is a valid marker of the visceral adipose tissue volume; in Angel A, Andersson H, Bouchard C, Lau L, Leiter L, Mendelson R (eds): Progress in Obesity Research: 7. London, Libbey, 1996, pp 309–319.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.